Objective: Cumulative data from clinical trials suggest that Lin28 may contribute to poor survival in breast cancer patients. The purpose of this study was to investigate the relationship between Lin28 expression and breast cancer patients’ clinicopathological parameters.
Methods: Data from a total of 291 breast cancer patients were collected in this study. The expression level of Lin28 was assessed by immunohistochemical staining. The correlation of Lin28 expression and clinicopathological parameters was statically evaluated and the prognostic significance of Lin28 expression was assessed by univariate and multivariate analyses.
Results: One hundred and eight out of 291 (37.1%) breast cancer specimens showed Lin28 protein positive expression, while the remaining 183 specimens showed negative expression. Positive expression of Lin28 was associated with lymph node metastases (P <0.001), HER-2 (P =0.024), estrogen receptor (P =0.039), and progesterone receptor (P =0.027). Kaplan–Meier analysis showed that Lin28 positive expression showed lower overall survival rates compared with Lin28 negative patients (P =0.019). In the multivariate analysis, Lin28 remained a significant independent prognostic factor (P =0.038) for overall survival rates.
Conclusion: Lin28 expression was associated with advanced disease stage and subtype in breast cancer patients, and Lin28 expression may serve as an independent prognostic factor. These data indicate that Lin28 may play a major role in the therapeutic management of breast cancer.
Keywords: breast cancer, Lin28, prognosis, estrogen receptor